Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic.

Anindita ChakrabortyJing PangGerald F WattsWendy BarnettAnn Marie WoodwardMary VorsterGerald F Watts

Published in: Clinical cardiology (2021)

PCSK9mAbs can effectively and safely lower plasma Lp(a) concentrations in patients with elevated Lp(a) in clinical practice; the impact of the fall in Lp(a) on ASCVD outcomes requires further investigation.

Keyphrases

low density lipoprotein
monoclonal antibody
clinical practice
randomized controlled trial
systematic review
primary care
tertiary care
metabolic syndrome
combination therapy
adipose tissue
glycemic control
insulin resistance
replacement therapy